|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma显示文摘 | Bennouna J Bompas E Neidhardt EM | 2008 | Cancer Immunol Immnnother2008，57，11： | 1 |
| 2 | Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gammagdelta2 T lymphocytes, in combina- tion with IL-2, in patients with metastatic renal cell carcino- ma显示文摘 | Bennouna J Bompas E Neidhardt EM | 2008 | Cancer Immunol Immunother2008，57，： | 1 |
| 3 | Phase-I study of Innacell gammadelta,an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes,in combination with IL-2,in patients with metastatic renal cell carcinoma显示文摘 | BENNOUNA J BOMPAS E NEIDHARDT E M | 2008 | Cancer Immunol Immunother2008，57，11： | 1 |
| 4 | Phase-1 studyof Innacell gammadelta,an autologous cell-therapy producthighly enriched in gamma9delta2 T lymphocytes,in combina-tion with IL-2,in patients with metastatic renal cell carcinoma显示文摘 | Bennouna J Bompas E Neidhardt E M | 2008 | Cancer Immunol Immunother2008，57，11： | 1 |
| 5 | Management of post - chemotherapy residual masses in advanced seminoma显示文摘 | Flechon A Bompas E Biron P | 2002 | J Urol2002，168，5： | 1 |
| 6 | Phase-Ⅰ study of Innacell γδTM,an autologous cell-thterapy product highly enuiched in γ9δ2 T lymphocytes,in combination with IL-2,in patients with metastatic renal cell carcinoma显示文摘 | Bennouna J Bompas E Neidhardt EM | 2008 | Cancer Immuol Immunother2008，57，11： | 1 |
| 7 | Phase-I study of In- nacell gammadelta, an autologous cell-therapy product highly en- riched in gamma9della2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma显示文摘 | Bennouna J Bompas E Neidhardt E M | 2008 | Cancer Immunol lmmunother2008，57，11： | 1 |
| 8 | Phase-I study of innacell γδTM,an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes,in combination with IL-2,in patients with metastatic renal cell carcinoma显示文摘 | Bennouna J Bompas E Marie E | 2008 | Cancer Immunol Immunother2008，57，11： | 1 |
| 9 | Phase- I study of innaceU gammadeltatrade mark, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes,in combination with IL-2, in patients with metastatic renal cell carcinoma 显示文摘 | Bennouna J Bompas E Neidhardt EM | 2008 | Cancer Immunol Immunother2008，57，11： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员